Jefferies Cuts Price Target on Immunomedics (IMMU) as Clivatuzumab Program is Discontinued
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
After-Hours Stock Movers 03/14: (CPXX) (SZYM) (ESI) Higher; (IMMU) (MNKD) (NVIV) Lower (more...)
March 14, 2016 6:09 PM EDTCelator Pharmaceuticals, Inc. (Nasdaq: CPXX) 373% HIGHER; announced positive results from the Phase 3 trial of VYXEOS (cytarabine: daunorubicin) Liposome for Injection (also known as CPX-351) in patients with high-risk (secondary) acute myeloid leukemia (AML) compared to the standard of care regimen of cytarabine and daunorubicin known as 7+3. The trial met its primary endpoint demonstrating a statistically significant improvement in overall survival.
Solazyme, Inc. (Nasdaq: SZYM) 29.5% HIGHER; has signed a definitive multi-year global supply agreement with Unilever.... More
Immunomedics (IMMU) to Terminate Phase 3 PANCRIT-1 w/ 90Y in Metastatic Pancreatic Cancer
March 14, 2016 4:31 PM EDTImmunomedics, Inc., (Nasdaq: IMMU) announced that the Company is terminating the Phase 3 PANCRIT-1 trial with yttrium-90-labeled (90Y) clivatuzumab tetraxetan in patients... More
